A Phase II Trial of Gemcitabine plus Capecitabine in Metastatic Renal Cell Cancer Previously Treated with Immunotherapy and Targeted Agents

PURPOSE: To assess the clinical activity and safety of gemcitabine (G) plus capecitabine (X) in metastatic renal cell cancer (mRCC) patients previously treated with immunotherapy. METHODS: In this phase II trial, patients received G 1000 mg/m(2) intravenously on days 1, 8 and 15, plus X 830 mg/m(2)...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Tannir, Nizar M., Thall, Peter F., Ng, Chaan S., Wang, Xuemei, Wooten, Leiko, Siefker-Radtke, Arlene, Mathew, Paul, Pagliaro, Lance, Wood, Christopher, Jonasch, Eric
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2008
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4167838/
https://ncbi.nlm.nih.gov/pubmed/18635226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2008.05.017
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi